Home > Insider Trading > Filing (0001209191-21-021571)

Filing Details

Accession Number:: 0001209191-21-021571
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-03-17 19:47:15
Reporting Period:: 2021-03-16

Accepted Time:: 2021-03-17 19:47:15
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1718852	Prometheus Biosciences Inc.	RXDX	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
905226	Cohen Steven A/Sac Capital Mgmt Lp	C/O Point72, L.p. 72 Cummings Point Road Stamford CT 06902	No	No	No	Yes
1832749	72 Investment Holdings, Llc	C/O Point72, L.p. 72 Cummings Point Road Stamford CT 06902	No	No	No	Yes
1850121	Differentiated Ventures Investments, Llc	C/O Point72, L.p. 72 Cummings Point Road Stamford CT 06902	No	No	No	Yes
1850122	Point72 Biotech Private Investments, Llc	C/O Point72, L.p. 72 Cummings Point Road Stamford CT 06902	No	No	No	Yes

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-03-16	763,327	$0.00	763,327	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-03-16	1,084,697	$0.00	1,848,024	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2021-03-16	800,000	$19.00	2,648,024	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D-1 Preferred Stock	Disposition	2021-03-16	7,633,277	$0.00	763,327	$0.00
Common Stock	Series D-2 Preferred Stock	Disposition	2021-03-16	10,846,968	$0.00	1,084,697	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The shares of the Issuer's Series D-1 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
The securities reported herein may be deemed to be beneficially owned by each: (i) Differentiated Ventures Investments, LLC (DVI), which is deemed the beneficial owner of shares held by Point72 Biotech Private Investments, LLC (Point72 Biotech), (ii) 72 Investment Holdings, LLC (72 IH), the sole member of DVI, deemed to have sole voting and investment control over such interest held by DVI, and (iii) Steven A. Cohen (SC), the sole member of 72 IH, deemed to have sole voting and investment control over such interest held by 72 IH. Each of SC, 72 IH, and DVI disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
The shares of the Issuer's Series D-2 Preferred Stock automatically converted into shares of the Issuer's common Stock, for no additional consideration, at a ratio of ten-for-one share, immediately prior to the consummation of the Issuer's initial public offering.
Point72 Associates, LLC (the Fund) is the direct owner of 800,000 shares of Common Stock. SC may be deemed to have an indirect pecuniary interest in such shares of Common Stock as an indirect holder of interests in the Fund.
Consist of shares of Series D-1 Preferred Stock held directly by Point72 Biotech.
Consist of shares of Series D-2 Preferred Stock held directly by Point72 Biotech.